Portola Pharmaceuticals (NASDAQ: PTLA) could win approvals from the Food and Drug Administration for two important new drugs in the coming year. Its drug betrixaban could become the first of a new class of drugs to be green-lighted for reducing the chance of blood clots forming in acute medically ill patients, and its AndexXa could become the first antidote approved to reverse the effects of top-selling anticoagulants that are already billion-dollar blockbusters.
Continue Reading Below
In this clip from The Motley Fool's Industry Focus: Healthcarepodcast, analyst Kristine Harjes and contributor Todd Campbell discuss the opportunity ahead for this biotech, and what's next on deck for investors.
A transcript follows the video.
10 stocks we like better than Portola Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Portola Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
Continue Reading Below
*Stock Advisor returns as of February 6, 2017
This podcast was recorded on March 6, 2017.
Kristine Harjes:We havearrived at our lastcompany of the day, which is also this year'sbiggest winner so far, up72%. This is a name that Todd and Italk about a lot. We both really like this company. That isPortola Pharmaceuticals.
Todd Campbell:Fulldisclosure, I happen to be long this one.
Harjes:As am I.
Campbell:It's been up72% so far this year. Took it on the chin last year, and now we're getting it back.
Harjes:Yeah, they were down 56% in 2016, which did not feel good,especially having to come on the show and be like, "Hey,we were really wrong." But maybe we weren't so wrong. Long-term investing, we're doing OK.
Campbell:The wholeconcept here --here's the takeaway for this company: They have got two drugs that could both be blockbuster drugs. And last year, they both stumbled in trying to get these drugs to the FDA. One of the drugs, Betrixaban, we talked about, put up very weirdmixed results in trialsearly last year, and that cast a lot of doubt onwhether or not the FDA would be willing to lookfavorably upon it once they filed their application forapproval.
The other one is AndexXa. AndexXa is used to reverse aclass of drugs called factor Xaanticoagulants that are used toprevent blood clots. There is no antidote on the market right now. However, last August the FDA sent them arejection letter because they wanted to get some more information from them. So, that was a one-two punch last year. Then,fast-forward to 2017, Kristine, and guess what? Betrixaban has been filed, and the FDA has said theydon't think they're going to need to do an ad-com meeting to discuss Betrixaban, which doesn'tguarantee an approval, butcertainly increases, in my view, the odds of a go-ahead. And AndexXa,supposedly, they're going to get that refiled soon, too. If they make good on their timeline, they think they could have an approval in handby the end of this year. So, theoretically, one blockbuster already on the market by late this year, and potentially twoon the market next year.
Harjes:Which is pretty incredible, and gives us a lot to look forward to,and I'm sure we'll be discussing them on the show again come June 24th, which is the PDUFA date for Betrixaban or whenever we get the next news about AndexXa.
Kristine Harjes owns shares of Portola Pharmaceuticals. Todd Campbell owns shares of Portola Pharmaceuticals. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.